Navigation Links
Million dollar boost to Alzheimer's and stroke research at Robarts
Date:9/6/2009

The Canadian Institutes of Health Research (CIHR) has announced a grant totaling more than a million dollars for John F. MacDonald's research on Alzheimer's disease. MacDonald is the Director of the Robarts Research Institute at The University of Western Ontario.

"If you have a stroke and survive, you have a very high risk of developing Alzheimer's disease or another dementia. These diseases are already taking a huge toll on society and costing billions of dollars in health care costs," says MacDonald. "With the aging population, it's a true growth illness."

The basic problem is how to prevent nerve cells in the brain from dying, and no longer being able to communicate information. The CIHR funding, which totals $1,086,625 over five years, will allow MacDonald to investigate the transmission process between nerve cells. In particular, he's interested in how a unique ion channel, TRPM2, couples with a glutamate receptor called NMDA to assist learning and memory. If this receptor becomes over-activated, for example during a stroke, it produces toxicity which damages or kills the brain cell. MacDonald has developed a peptide which will be tested to see if it'll prevent this toxic interaction, without interfering with normal activity.

MacDonald is also one of the co-authors of a Stroke-related study in the September 6th Advance Online Publication of the prestigious journal Nature Neuroscience. Scientists from the University of Toronto, Robarts Research Institute, the Mayo Clinic in Florida, and Kyoto University in Japan identified a way to prevent the death of neurons in the brain by inhibiting the expression of a channel called TRPM7. Michael Tymianski of Toronto was the lead on the study.

MacDonald is collaborating with researchers in Toronto, Japan and Ireland on the CIHR project. He's also part of an informal network of researchers across Canada dedicated to finding ways to prevent and treat Alzheimer's disease. "Finding new types of pharmacological therapy for Alzheimer's and related diseases is likely the most important health and social concern for Canada and the developed world."


'/>"/>

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
3. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
4. 1.5 million children could be saved
5. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
6. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
9. £5 million investment in personalized medicines to cut patient deaths
10. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 million SharePoint ... option for on-premises installation of its Help System for SharePoint was at the farm ... into the entire tenant. , The company recently released a modified version of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the annual ... the Diabetes Risk Test to find out if they are at risk for developing ... light up the evening sky by programming the LAX pylons the color red. Downtown’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati Technologies ... directly address the resolution to globally reduce the harmful use of alcohol set ... FDA and TTB approved ingredients that when infused into alcohol, renders the alcohol ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to be invited to the Siemens Healthineers annual customer education symposium, a world-class ... will take place from March 27 - 31, 2017 at the Atlanta Marriott ...
(Date:3/28/2017)... ... March 29, 2017 , ... ... pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March ... common questions regarding thyroid function. , Dr. Izabella Wentz is a licensed ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... Treated at Proton Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in ... from its market value in 2016. There are currently three proton therapy ... capacity to treat more patients. In Italy , the ...
(Date:3/29/2017)... 29, 2017  Providence Medical Technology, Inc., an ... of two industry veterans to the commercial leadership ... company to lead Global Marketing, and Michael ... Lynch and Mr. Scott have over 40 years ... Lynch joins the company with over 22 years ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
Breaking Medicine Technology: